CX516

DB06247InvestigationalSmall molecule

Investigated for use/treatment in alzheimer's disease, memory loss, autism, neurologic disorders, dementia, schizophrenia and schizoaffective disorders, attention deficit/hyperactivity disorder (ADHD), and sleep disorders.

Mechanism: CX 516 is a benzylpiperidine AMPAkine, an AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) modulator, that enhances the function of glutamate when it binds allosterically to the AMPA receptor channel complex. CX 516 slows receptor deactivation with a longer open time, slower excitatory postsynaptic potential (EPSP) decay and improvement of hippocampal long term potentiation (LTP).
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, memory loss, autism, neurologic disorders, dementia, schizophrenia and schizoaffective disorders, attention deficit/hyperactivity disorder (ADHD), and sleep disorders.Curator reviewed
Formula / weight: C₁₄H₁₅N₃O · 241.2884 g/mol (avg)
Code names: BDP-12 · CX-516

Resolves to

Compound

UNIIZ5QU38B4V9CAS154235-83-3ChEMBLCHEMBL136800ChEBI34605KEGGC13675

Structure

InChIKeyANDGGVOPIJEHOF-UHFFFAOYSA-NSMILESO=C(N1CCCCC1)C1=CC2=C(C=C1)N=CC=N2

Targets

P42261GRIA1

What you can answer from here — as of June 12, 2020

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with CX516, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account